FibroGen’s (NASDAQ:FGEN) Buy Rating Reaffirmed at Citigroup Inc.

Citigroup Inc. reissued their buy rating on shares of FibroGen, Inc (NASDAQ:FGEN) in a research report released on Monday, June 26th. Citigroup Inc. currently has a $48.00 target price on the biopharmaceutical company’s stock.

FGEN has been the topic of a number of other research reports. Zacks Investment Research downgraded FibroGen from a hold rating to a sell rating in a report on Monday, May 8th. William Blair reissued an outperform rating on shares of FibroGen in a report on Monday, June 26th. BidaskClub upgraded FibroGen from a buy rating to a strong-buy rating in a research report on Saturday, June 24th. Finally, Stifel Nicolaus restated a buy rating and issued a $38.00 target price (up from $32.00) on shares of FibroGen in a research report on Thursday, June 22nd. One investment analyst has rated the stock with a sell rating, seven have given a buy rating and one has issued a strong buy rating to the stock. The stock has a consensus rating of Buy and an average target price of $42.17.

FibroGen (NASDAQ FGEN) traded up 1.79% during midday trading on Monday, hitting $34.10. 54,617 shares of the stock traded hands. The firm’s market cap is $2.39 billion. FibroGen has a 12 month low of $15.60 and a 12 month high of $34.25. The company’s 50 day moving average price is $28.77 and its 200 day moving average price is $25.52.

FibroGen (NASDAQ:FGEN) last issued its quarterly earnings results on Tuesday, May 9th. The biopharmaceutical company reported ($0.52) EPS for the quarter, beating analysts’ consensus estimates of ($0.63) by $0.11. The firm had revenue of $26.89 million during the quarter, compared to the consensus estimate of $26.02 million. FibroGen had a negative return on equity of 36.41% and a negative net margin of 37.60%. Equities research analysts predict that FibroGen will post ($1.85) earnings per share for the current fiscal year.

WARNING: This piece was first published by Chaffey Breeze and is the property of of Chaffey Breeze. If you are accessing this piece on another site, it was copied illegally and republished in violation of US and international trademark & copyright laws. The correct version of this piece can be accessed at https://www.chaffeybreeze.com/2017/07/17/fibrogen-inc-fgen-given-buy-rating-at-citigroup-inc-updated-updated.html.

In other news, CEO Thomas B. Neff sold 18,900 shares of the business’s stock in a transaction that occurred on Monday, April 24th. The stock was sold at an average price of $26.35, for a total value of $498,015.00. Following the transaction, the chief executive officer now directly owns 3,345,941 shares of the company’s stock, valued at approximately $88,165,545.35. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, VP Pat Cotroneo sold 4,000 shares of the company’s stock in a transaction on Thursday, July 6th. The stock was sold at an average price of $34.00, for a total value of $136,000.00. Following the transaction, the vice president now directly owns 167,366 shares in the company, valued at approximately $5,690,444. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 381,128 shares of company stock worth $11,124,449. Corporate insiders own 14.90% of the company’s stock.

Hedge funds have recently modified their holdings of the stock. Acadian Asset Management LLC boosted its stake in FibroGen by 1,455.0% in the first quarter. Acadian Asset Management LLC now owns 148,490 shares of the biopharmaceutical company’s stock worth $3,661,000 after buying an additional 138,941 shares in the last quarter. FMR LLC boosted its stake in FibroGen by 72.5% in the fourth quarter. FMR LLC now owns 1,533,431 shares of the biopharmaceutical company’s stock worth $32,815,000 after buying an additional 644,528 shares in the last quarter. Renaissance Technologies LLC boosted its stake in FibroGen by 48.9% in the fourth quarter. Renaissance Technologies LLC now owns 332,600 shares of the biopharmaceutical company’s stock worth $7,118,000 after buying an additional 109,300 shares in the last quarter. Sphera Funds Management LTD. boosted its stake in FibroGen by 6.4% in the first quarter. Sphera Funds Management LTD. now owns 165,700 shares of the biopharmaceutical company’s stock worth $4,085,000 after buying an additional 10,000 shares in the last quarter. Finally, ClariVest Asset Management LLC bought a new position in shares of FibroGen during the first quarter worth $2,065,000. Institutional investors own 43.83% of the company’s stock.

FibroGen Company Profile

FibroGen, Inc is a science-based biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of therapeutics to treat serious unmet medical needs. Its lead product candidate is roxadustat (FG-4592). It is also engaged in developing products, such as FG-6874, FG-3019 and FG-5200.

Analyst Recommendations for FibroGen (NASDAQ:FGEN)

Receive News & Ratings for FibroGen Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for FibroGen Inc and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply